Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.36 |
| ▸ | SLC2A4 | P14672 | 2/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 8/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139859 | 0.80 | TLR7 (0.53) | TLR7 | |
| SCHEMBL4144495 | 0.69 | TLR7 (0.74) | TLR7 | |
| SCHEMBL4136692 | 0.69 | TLR7 (0.74) | TLR7 | |
| SCHEMBL4152858 | 0.69 | TLR7 (0.72) | TLR7 | |
| SCHEMBL13849531 | 0.66 | TLR7 (0.79) | TLR7 | |
| SCHEMBL4127893 | 0.66 | TLR7 (0.73) | TLR7 | |
| SCHEMBL4128442 | 0.66 | TLR7 (0.72) | TLR7 | |
| SCHEMBL13849532 | 0.64 | TLR7 (0.57) | TLR7 | |
| SCHEMBL14025120 | 0.64 | ACHE (0.49) | ACHEBCHECYP2D6 | |
| SCHEMBL4577771 | 0.63 | ALDH1A1 (0.51) | ACHEBCHECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | TLR7 389/4885SLC2A1 747/4885SLC2A4 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.